Subconjunctival Adalimumab for Noninfectious Uveitis: A Prospective Pilot Study.

IF 2.6 4区医学 Q2 OPHTHALMOLOGY

Ocular Immunology and Inflammation Pub Date : 2025-05-27 DOI:10.1080/09273948.2025.2512170

Soumyava Basu, Sucheta Ireni, Mudit Tyagi, Thomas H Dohlman, Eleftherios I Paschalis

{"title":"Subconjunctival Adalimumab for Noninfectious Uveitis: A Prospective Pilot Study.","authors":"Soumyava Basu, Sucheta Ireni, Mudit Tyagi, Thomas H Dohlman, Eleftherios I Paschalis","doi":"10.1080/09273948.2025.2512170","DOIUrl":null,"url":null,"abstract":"Aim: To evaluate the safety and preliminary efficacy of low-dose subconjunctival adalimumab in patients with non-infectious uveitis (NIU), refractory to conventional immunomodulatory therapy (IMT).Methods: Prospective, noncomparative, interventional case series. Five patients with bilateral panuveitis (four post-therapeutic vitrectomy) and persistent intraocular inflammation on conventional IMT for > 2 years received three doses of subconjunctival adalimumab 5 mg/0.1 mL at two-week intervals and followed up for 24 weeks.Results: No cases of persistent conjunctival congestion, corneal erosions or infection, or intraocular pressure > 21 mmHg were noted. Improvement in inflammatory scores and best-corrected visual acuity (BCVA) were noted in three patients each and worsening in none. None of the three patients who showed initial improvement in visual acuity had any baseline cystoid macular edema or vitreous haze to account for the improvement in BCVA.Conclusion: Subconjunctival administration of 5 mg adalimumab is a safe and effective therapy for NIU refractory to conventional IMT.","PeriodicalId":19406,"journal":{"name":"Ocular Immunology and Inflammation","volume":" ","pages":"1-3"},"PeriodicalIF":2.6000,"publicationDate":"2025-05-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ocular Immunology and Inflammation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09273948.2025.2512170","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Aim: To evaluate the safety and preliminary efficacy of low-dose subconjunctival adalimumab in patients with non-infectious uveitis (NIU), refractory to conventional immunomodulatory therapy (IMT).

Methods: Prospective, noncomparative, interventional case series. Five patients with bilateral panuveitis (four post-therapeutic vitrectomy) and persistent intraocular inflammation on conventional IMT for > 2 years received three doses of subconjunctival adalimumab 5 mg/0.1 mL at two-week intervals and followed up for 24 weeks.

Results: No cases of persistent conjunctival congestion, corneal erosions or infection, or intraocular pressure > 21 mmHg were noted. Improvement in inflammatory scores and best-corrected visual acuity (BCVA) were noted in three patients each and worsening in none. None of the three patients who showed initial improvement in visual acuity had any baseline cystoid macular edema or vitreous haze to account for the improvement in BCVA.

Conclusion: Subconjunctival administration of 5 mg adalimumab is a safe and effective therapy for NIU refractory to conventional IMT.

查看原文本刊更多论文

结膜下阿达木单抗治疗非感染性葡萄膜炎：一项前瞻性试点研究。

目的：评价低剂量结膜下阿达木单抗治疗传统免疫调节治疗（IMT）难治性非感染性葡萄膜炎（NIU）患者的安全性和初步疗效。方法：前瞻性、非比较性、干预性病例系列。5例双侧全葡萄膜炎（4例治疗后玻璃体切除术）和持续眼内炎症的患者接受常规IMT治疗bbb20年，每隔两周接受三次结膜下阿达木单抗5 mg/0.1 mL，随访24周。结果：无持续性结膜充血、角膜糜烂或感染、眼压低于21 mmHg的病例。3例患者炎症评分和最佳矫正视力（BCVA）均有改善，无患者恶化。最初视力改善的3名患者中没有任何基线囊样黄斑水肿或玻璃体浑浊来解释BCVA的改善。结论：5mg阿达木单抗结膜下给药是一种安全有效的治疗传统IMT难治性NIU的方法。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ocular Immunology and Inflammation 医学-眼科学

CiteScore

6.20

自引率

15.20%

发文量

285

审稿时长

6-12 weeks

期刊介绍： Ocular Immunology & Inflammation ranks 18 out of 59 in the Ophthalmology Category.Ocular Immunology and Inflammation is a peer-reviewed, scientific publication that welcomes the submission of original, previously unpublished manuscripts directed to ophthalmologists and vision scientists. Published bimonthly, the journal provides an international medium for basic and clinical research reports on the ocular inflammatory response and its control by the immune system. The journal publishes original research papers, case reports, reviews, letters to the editor, meeting abstracts, and invited editorials.